Other languages NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

End-of-day quote Korea S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
1,770 ^KRW	-4.48%		-7.28%	-12.59%

02/04	NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	CI
15/01	NeoImmuneTech, Inc. Appoints Luke Oh as President	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	02/04
NeoImmuneTech, Inc. Appoints Luke Oh as President	15/01
Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome	20/11
Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board	26/23/26
NeoImmuneTech, Inc. to Partner with U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health for Drug Development in Acute Radiation Syndrome	03/23/03
New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors	11/22/11
NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board	08/22/08
NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity	15/22/15
NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors	06/22/06
Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022	13/22/13
NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers	07/22/07
NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7	24/22/24
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	28/21/28
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	25/21/25
NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global Technology, Inc.	25/21/25
NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting	22/21/22
NeoImmuneTech, Inc. Presents Data in Three Posters At Society for Immunotherapy of Cancer Annual Meeting	16/21/16
NeoimmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (Efineptakin Alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer	08/21/08
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma	13/21/13
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting	04/21/04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

Other languages

Filters